UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Public ClinicalTrials.gov record NCT02722668. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen with modifications based on factors including diagnosis, disease status, and prior treatment. Single or double unit selected according to current University of Minnesota umbilical cord blood graft selection algorithm.
Study identification
- NCT ID
- NCT02722668
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 15 participants
Conditions and interventions
Conditions
- Acute Leukemia
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia/Lymphoma
- Burkitt's Lymphoma
- Natural Killer Cell Malignancies
- Chronic Myelogenous Leukemia
- Myelodysplastic Syndrome
- Large-cell Lymphoma
- Hodgkin Lymphoma
- Multiple Myeloma
- Relapsed Chronic Lymphocytic Leukemia
- Relapsed Small Lymphocytic Lymphoma
- Marginal Zone B-cell Lymphoma
- Follicular Lymphoma
- Lymphoplasmacytic Lymphoma
- Mantle-cell Lymphoma
- Prolymphocytic Leukemia
- Bone Marrow Failure Syndromes
- Myeloproliferative Neoplasms/Myelofibrosis
- Biphenotypic/Undifferentiated/Prolymphocytic Leukemias
- MRD Positive Leukemia
- Leukemia or MDS in Aplasia
- Relapsed T-Cell Lymphoma
- Relapsed Multiple Myeloma
- Plasma Cell Leukemia
Interventions
- Fludarabine Drug
- Cyclophosphamide Drug
- MMF Drug
- Sirolimus Drug
- TBI Radiation
- Umbilical cord blood cell infusion Biological
- ATG Biological
Drug · Radiation · Biological
Eligibility (public fields only)
- Age range
- Up to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 14, 2017
- Primary completion
- Feb 21, 2023
- Completion
- Feb 21, 2024
- Last update posted
- Jul 3, 2025
2017 – 2024
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Masonic Cancer Center at University of Minnesota | Minneapolis | Minnesota | 55455 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02722668, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 3, 2025 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02722668 live on ClinicalTrials.gov.